EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Tag

keytruda

Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

What are the takeaways from recent mixed trial results for Keytruda in gastric cancer? Dr. Mark Zalupski of University of Michigan weighs...

‹ Previous 1 2

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

15 hours ago

The FDA approved BeiGene’s Tevimbra plus chemotherapy to treat metastatic gastric cancer. The approval was based on trial data showing a clinically meaningful improvement in overall survival. ... See MoreSee Less

Tislelizumab Plus Chemotherapy Receives FDA Approval for First-Line Treatment of Advanced Gastric Cancer

www.oncnursingnews.com

The FDA approved tislelizumab plus chemotherapy for the first-line treatment of unresectable or metastatic gastric or GEJ adenocarcinoma.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 days ago

At American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025, Agenus will discuss its investigative treatment combining two antibodies with natural killer T cells in gastric cancer. ... See MoreSee Less

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

www.biospace.com

Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal cancer, including the neoadjuvant setting

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 weeks ago

Researchers at Cleveland Clinic developed a machine learning model that uses data from electronic health records to find patients most at risk for gastric cancer. The model incorporated data from 11,000 patients—including 567 with gastric cancer—and predicted gastric cancer risk with surprising accuracy. Researchers reported at the 2024 American College of Gastroenterology Annual Scientific Meeting. ... See MoreSee Less

Model Uses Machine Learning to Predict Patients at Risk of Gastric Cancer

consultqd.clevelandclinic.org

New research from Cleveland Clinic shows how a machine learning model could help clinicians better identify patients with a high risk for gastric cancer.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 weeks ago

Researchers at the MD Anderson Cancer Center discovered an enzyme, SMYD5, that fuels cancer growth by stimulating the production of certain proteins. They found that in mouse models of gastric cancer, targeting SMYD5 slowed down tumor growth and improved the efficacy of CAR-T cell therapy. ... See MoreSee Less

Enzyme discovery heralds new target for gastric cancer treatment

www.nature.com

Blocking enzyme SMYD5 inhibits tumour growth and primes lab models for combination therapy, offering hope for more effective treatments.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 weeks ago

In preclinical studies, combining the experimental drug pelcitoclax with chemotherapy was effective against HER2-positive gastric cancer. The drug is designed to overcome resistance to HER2-targeted drugs by binding to two tumor targets and inducing the death of cancer cells. ... See MoreSee Less

The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer - Acta Pharmacologica Sinica

www.nature.com

HER2-positive gastric cancer has a poor prognosis, with a high incidence of drug resistance and a lack of effective treatments for drug-resistant patients. The exploration of the mechanism of resistan...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X